These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25356663)

  • 1. Testing assay linearity over a pre-specified range.
    Yang H; Novick SJ; LeBlond D
    J Biopharm Stat; 2015; 25(2):339-50. PubMed ID: 25356663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical procedure validation and the quality by design paradigm.
    Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
    J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
    Tsong Y; Yang H
    J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
    [No Abstract]   [Full Text] [Related]  

  • 6. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
    Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
    J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
    Fan Z; Zhang L
    J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A statistical approach to determining criticality of residual host cell DNA.
    Yang H; Wei Z; Schenerman M
    J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Generalized Pivotal Quantity Approach to Analytical Method Validation Based on Total Error.
    Yang H; Zhang J
    PDA J Pharm Sci Technol; 2015; 69(6):725-35. PubMed ID: 26659103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of the probability of passing the USP dissolution test.
    Wang H
    J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On statistical evaluation of the linearity in assay validation.
    Hsieh E; Liu JP
    J Biopharm Stat; 2008; 18(4):677-90. PubMed ID: 18607801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexibility and applicability of β-expectation tolerance interval approach to assess the fitness of purpose of pharmaceutical analytical methods.
    Bouabidi A; Talbi M; Bourichi H; Bouklouze A; El Karbane M; Boulanger B; Brik Y; Hubert P; Rozet E
    Drug Test Anal; 2012 Dec; 4(12):1014-27. PubMed ID: 22615163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing parallelism prior to determining relative potency.
    Hauck WW; Capen RC; Callahan JD; De Muth JE; Hsu H; Lansky D; Sajjadi NC; Seaver SS; Singer RR; Weisman D
    PDA J Pharm Sci Technol; 2005; 59(2):127-37. PubMed ID: 15971545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.
    Christopher D; Adams W; Amann A; Bertha C; Byron PR; Doub W; Dunbar C; Hauck W; Lyapustina S; Mitchell J; Morgan B; Nichols S; Pan Z; Singh GJ; Tougas T; Tsong Y; Wolff R; Wyka B
    AAPS PharmSciTech; 2007 Nov; 8(4):E90. PubMed ID: 18181550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the recovery spread in analytical development and routine quality control--based on the ICH quality guideline Q2B.
    Schepers U; El Deeb S; Ermer J; Wätzig H
    J Pharm Biomed Anal; 2007 Jan; 43(2):708-10. PubMed ID: 16904281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple Approach to Calculate Random Effects Model Tolerance Intervals to Set Release and Shelf-Life Specification Limits of Pharmaceutical Products.
    Montes RO; Burdick RK; Leblond DJ
    PDA J Pharm Sci Technol; 2019; 73(1):39-59. PubMed ID: 30361286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.